Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

IHE's concentrated pharma focus delivered 50% gains versus IYH's 27.4%, though the broader healthcare fund offers more diversification and $3.9B in assets.

Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

Published September 8, 2026 · Category: Finance

Overview

The iShares U.S. Healthcare ETF (NYSEMKT:IYH) provides a broad basket covering medical providers, devices, and biotechnology, while iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers concentrated exposure strictly to the drug manufacturing industry.

Investors seeking healthcare exposure often choose between niche subsectors, such as drug manufacturing, and broader industry baskets. Both iShares U.S. Pharmaceuticals ETF and iShares U.S. Healthcare ETF are managed by iShares, a division of BlackRock Inc (NYSE:BLK), but they differ significantly in their scope. While the former focuses strictly on pharmaceutical giants, the latter represents a more diverse range of medical services and technologies.

Details

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the end of the trading day on Aug. 27, 2026.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.